The Role of chemokine receptor CXCR4 in breast cancer metastasis.
The Role of chemokine receptor CXCR4 in breast cancer metastasis.
复制标题
DOI：
--
复制
发表时间：
2013
影响因子：
5.3
通讯作者：
Debarati Mukherjee;Jihe Zhao
中科院分区：
文献类型：
--
作者：
Debarati Mukherjee;Jihe Zhao
乳腺癌是全球癌症相关死亡的主要原因之一。乳腺癌相关死亡率与原发肿瘤病灶转移潜能的发展相关。已发现趋化因子受体CXCR 4是包括乳腺癌在内的各种类型癌症的预后标志物。癌症生物学领域的最新进展已经指出CXCR 4受体及其配体CXCL 12在包括乳腺癌在内的各种类型癌症的转移中发挥关键作用。乳腺肿瘤优先转移到肺、骨和淋巴结，所有这些都代表了分泌高水平CXCL 12的器官。CXCL 12作为一种趋化因子，驱使CXCR 4阳性原发性肿瘤细胞向继发性转移部位转移，导致转移性病变的发生。自2001年发现以来，CXCR 4领域的进展非常快，进一步的研究指出了CXCR 4在肿瘤细胞从原发部位扩散、肿瘤细胞的跨内皮迁移以及癌症干细胞的运输和归巢中的作用。本文综述了近年来CXCL 12-CXCR 4信号通路在乳腺癌中的作用，讨论了其在乳腺癌控制新治疗工具开发中的潜在应用，并阐明了未来潜在的治疗挑战和该领域改善乳腺癌患者预后的未来方向。
Breast cancer is one of the leading causes of cancer related deaths worldwide. Breast cancer-related mortality is associated with the development of metastatic potential of primary tumor lesions. The chemokine receptor CXCR4 has been found to be a prognostic marker in various types of cancer, including breast cancer. Recent advances in the field of cancer biology has pointed to the critical role that CXCR4 receptor and its ligand CXCL12 play in the metastasis of various types of cancer, including breast cancer. Breast tumors preferentially metastasize to the lung, bones and lymph nodes, all of which represent organs that secrete high levels of CXCL12. CXCL12 acts as a chemoattractant that drives CXCR4-positive primary tumor cells towards secondary metastatic sites leading to the onset of metastatic lesions. Since its discovery in 2001, the CXCR4 field has progressed at a very fast rate and further studies have pointed to the role of CXCR4 in dissemination of tumor cells from primary sites, transendothelial migration of tumor cells as well as the trafficking and homing of cancer stem cells. This review summarizes the information that has been obtained over the years regarding the role of CXCL12-CXCR4 signaling in breast cancer, discusses its potential application to the development of new therapeutic tools for breast cancer control, and elucidates the potential therapeutic challenges which lie ahead and the future directions that this field can take for the improvement of prognosis in breast cancer patients.